Key result
Sitaxsentan reduced 24-hour proteinuria (-0.56±0.20 g/d; P=0.0069), blood pressure, and arterial stiffness compared with placebo in patients with proteinuric chronic kidney disease.
Why the study?
Does sitaxsentan reduce proteinuria, blood pressure, and arterial stiffness in patients with proteinuric chronic kidney disease?
Population
27 subjects with proteinuric chronic kidney disease on recommended renoprotective treatment
Comparison
Sitaxsentan 100 mg once daily for 6 weeks vs Placebo for 6 weeks, and nifedipine long-acting…
Design
RCT, randomized, double-blind
Follow-up
6 weeks per treatment period
Authors
Loading...
Supports add-on sitaxsentan in proteinuric CKD on optimal therapy; extends selective ET-A antagonism to stiffness and proteinuria reduction.
RCT (n=27)
double-blind
randomized
Does sitaxsentan reduce proteinuria, blood pressure, and arterial stiffness in patients with proteinuric chronic kidney disease?
Mean Difference: -0.56
p-value: p=0.0069
Selective endothelin-A receptor antagonism with sitaxsentan provides additional reduction in proteinuria, blood pressure, and arterial stiffness in patients with chronic kidney disease already on optimal renoprotective therapy.
Dhaun et al. (2011) conducted an RCT in proteinuric chronic kidney disease (n=27). sitaxsentan vs. placebo and nifedipine long acting (30 mg once daily) was evaluated on 24-hour proteinuria (MD -0.56 g/d, p=0.0069). Sitaxsentan reduced 24-hour proteinuria (-0.56±0.20 g/d; P=0.0069), blood pressure, and arterial stiffness compared with placebo in patients with proteinuric chronic kidney disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: